BR112013015957B1 - Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit - Google Patents

Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit Download PDF

Info

Publication number
BR112013015957B1
BR112013015957B1 BR112013015957-0A BR112013015957A BR112013015957B1 BR 112013015957 B1 BR112013015957 B1 BR 112013015957B1 BR 112013015957 A BR112013015957 A BR 112013015957A BR 112013015957 B1 BR112013015957 B1 BR 112013015957B1
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
naltrexone
acceptable salt
bupropion
binge eating
Prior art date
Application number
BR112013015957-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013015957A2 (pt
Inventor
Susan McElroy
Eduardo Dunayevich
Ron Landbloom
Original Assignee
Nalpropion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013015957(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc
Publication of BR112013015957A2 publication Critical patent/BR112013015957A2/pt
Publication of BR112013015957B1 publication Critical patent/BR112013015957B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112013015957-0A 2010-12-03 2011-12-02 Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit BR112013015957B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41935410P 2010-12-03 2010-12-03
US61/419,354 2010-12-03
PCT/US2011/063170 WO2012075453A1 (en) 2010-12-03 2011-12-02 Methods for reducing binge or compulsive eating

Publications (2)

Publication Number Publication Date
BR112013015957A2 BR112013015957A2 (pt) 2019-10-29
BR112013015957B1 true BR112013015957B1 (pt) 2021-07-20

Family

ID=46172302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015957-0A BR112013015957B1 (pt) 2010-12-03 2011-12-02 Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit

Country Status (26)

Country Link
US (2) US20130252995A1 (zh)
EP (1) EP2646011B1 (zh)
JP (1) JP2014508717A (zh)
KR (1) KR20140035319A (zh)
CN (1) CN103298462A (zh)
AR (2) AR084093A1 (zh)
AU (3) AU2011336298B2 (zh)
BR (1) BR112013015957B1 (zh)
CA (1) CA2819003A1 (zh)
CL (1) CL2013001565A1 (zh)
CY (1) CY1119560T1 (zh)
DK (1) DK2646011T3 (zh)
ES (1) ES2647232T3 (zh)
HR (1) HRP20171678T1 (zh)
HU (1) HUE034641T2 (zh)
IL (1) IL226483A0 (zh)
LT (1) LT2646011T (zh)
MX (1) MX350304B (zh)
NO (1) NO2646011T3 (zh)
PL (1) PL2646011T3 (zh)
PT (1) PT2646011T (zh)
RS (1) RS56548B1 (zh)
RU (1) RU2620913C2 (zh)
SI (1) SI2646011T1 (zh)
TW (2) TW201735912A (zh)
WO (1) WO2012075453A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197250C2 (ru) * 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
ATE460925T1 (de) 2006-11-09 2010-04-15 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
CA2709861A1 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical compositions
AU2011326173B2 (en) * 2010-11-08 2015-08-27 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors

Also Published As

Publication number Publication date
LT2646011T (lt) 2017-11-10
WO2012075453A1 (en) 2012-06-07
HUE034641T2 (en) 2018-02-28
MX2013006070A (es) 2013-07-29
TWI536986B (zh) 2016-06-11
US20130252995A1 (en) 2013-09-26
AR124497A2 (es) 2023-04-05
DK2646011T3 (da) 2017-11-20
EP2646011A4 (en) 2014-04-23
ES2647232T3 (es) 2017-12-20
EP2646011A1 (en) 2013-10-09
MX350304B (es) 2017-09-04
CL2013001565A1 (es) 2014-04-04
TW201735912A (zh) 2017-10-16
AU2011336298A1 (en) 2013-07-11
BR112013015957A2 (pt) 2019-10-29
AU2017202793A1 (en) 2017-05-18
AU2018203921A1 (en) 2018-06-21
PL2646011T3 (pl) 2018-01-31
RU2620913C2 (ru) 2017-05-30
CN103298462A (zh) 2013-09-11
SI2646011T1 (en) 2018-01-31
AU2017202793B2 (en) 2018-03-08
AU2011336298B2 (en) 2017-03-02
IL226483A0 (en) 2013-07-31
CA2819003A1 (en) 2012-06-07
EP2646011B1 (en) 2017-08-16
RU2013127420A (ru) 2015-01-10
PT2646011T (pt) 2017-11-17
RS56548B1 (sr) 2018-02-28
JP2014508717A (ja) 2014-04-10
TW201228659A (en) 2012-07-16
AR084093A1 (es) 2013-04-17
HRP20171678T1 (hr) 2017-12-15
US20210283126A1 (en) 2021-09-16
NO2646011T3 (zh) 2018-01-13
KR20140035319A (ko) 2014-03-21
CY1119560T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
AU2017202793B2 (en) Methods for Reducing Binge or Compulsive Eating
US11033543B2 (en) Methods of providing weight loss therapy in patients with major depression
JPH04507091A (ja) 体重減量医薬組成物
Nishioka et al. The concept of aggressive nutrition therapy and clinical indication: A position paper
Lu et al. An integrated approach to individualized optimal dose estimation of medication by means of dosing adjustment measures and Bi-Digital O-Ring Test
Ghai et al. An epidemiological investigation of insomnia: A survey
WO2007073134A1 (es) Composiciones farmaceuticas que comprenden sustancias inhibidoras de las lipasas intestinales combinadas con un complejo o-coordinado de dinicotinato de cromo para su uso en el tratamiento y control de la obesidad o sobrepeso
RU2788450C2 (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией
Montagno et al. Pharmacy in the News
Gentile Enteral nutrition as a life-saving treatment in patients with severe anorexia nervosa
Markowitz Body mass index and disordered eating in adolescent females with type 1 diabetes
Van der Westhuizen Obesity: evidence-based pharmacy practice
Liebenberg The Lipid-Modifying Properties of VasostateTM in Males
Hecker THE PCCA BLOG
Vansant Share this story: RELATED ARTICLES

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: NALPROPION PHARMACEUTICALS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: NALPROPION PHARMACEUTICALS LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2011, OBSERVADAS AS CONDICOES LEGAIS.